From a CRISPR baby to a young AI disruptor, 2025 has seen some serious leaps in science and technology. It's also seen some ...

The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 will be the year of the ...

Beam Therapeutics BEAM is engaged in developing investigational gene therapy candidates that are currently in ...

Gene editing has moved from theory to bedside with a speed that would have seemed impossible a decade ago. A new wave of ...

Explore how nanotechnology acts as the 'Convergence Engine' for AI materials discovery, CRISPR gene therapy delivery, and ...

Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the ...

A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly ...

CRISPR Therapeutics (NASDAQ:CRSP) is one of the best emerging technology stocks to invest in. On December 22, CRISPR Therapeutics released a comprehensive clinical update on zugocaptagene geleucel ...

Furthermore, it benefits from a strong competitive edge, thanks to its relationships with third-party payers, patients, and ...

A dire wolf de-extinction debate, CRISPR-GPT for gene editing, and more topped the list of our most popular stories in ...

CRISPR Therapeutics (NASDAQ: CRSP) soared a few years ago, climbing more than 200% from the start of 2020 through early 2021, ...

It was the best of times, it was the worst of times for research in 2025. | It was the best of times and it was the worst of times for research in 2025. Medical breakthroughs and stunning discoveries ...